H

Hypera S.A.

BVMF-HYPE3
Brazil Stock Exchange
Healthcare Drug Manufacturers - Specialty & Generic
Global Rank
#4911
Country Rank
#53
Market Cap
$2.93 B
Price
$4.62
Change (%)
0.58%
Volume
849,900

Hypera S.A.'s latest marketcap:

$2.93 B

As of 07/29/2025, Hypera S.A.'s market capitalization has reached $2.93 B. According to our data, Hypera S.A. is the 4911th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap $2.93 B
Revenue (ttm) $1.2 B
Net Income (ttm) $145.23 M
Shares Out 631.8 M
EPS (ttm) $0.23
Forward PE 9.55
Ex-Dividend Date 06/27/2025
Earnings Date 08/07/2025
Market Cap Chart
Data Updated: 07/29/2025

Hypera S.A.'s yearly market capitalization.

Hypera S.A. has seen its market value grow from R$10.52 B to R$16.34 B since 2014, representing a total increase of 55.31% and an annual compound growth rate (CAGR) of 4.25%.
Date Market Cap(R$) Market Cap(USD) Change (%) Global Rank
07/29/2025 R$16.34 B $2.93 B 44.96% 4911
12/30/2024 R$11.45 B $1.84 B -49.4% 6006
12/28/2023 R$22.62 B $4.65 B -20.96% 3030
12/29/2022 R$28.61 B $5.39 B 60.1% 2537
12/30/2021 R$17.87 B $3.19 B -17.59% 4515
12/30/2020 R$21.69 B $4.16 B -3.61% 3279
12/30/2019 R$22.5 B $5.59 B 17.88% 2194
12/28/2018 R$19.09 B $4.92 B -16.12% 2051
12/28/2017 R$22.76 B $6.86 B 38.24% 1828
12/29/2016 R$16.46 B $5.05 B 19.93% 1921

Company Profile

About Hypera S.A.

Hypera S.A. is a leading pharmaceutical company based in Brazil, specializing in prescription drugs, over-the-counter medications, skincare products, and nutritional supplements. Formerly known as Hypermarcas S.A., the company rebranded to Hypera S.A. in February 2018.

Product Portfolio

Prescription Pharmaceuticals: The company offers a wide range of prescription medications under brands such as:

  • Adacne, Addera, apri, AmpliumG
  • Celestamine, Celestone, Diprosone, diprospan
  • Emprol XR, Garasone, Halobex, Lipanon
  • Nesina, Novotram, PredSim, Quadriderm

Skincare & Over-the-Counter Products: Hypera provides sun protection, moisturizers, and OTC drugs under brands like:

  • Mantecorp Skincare, Doralgina, Benegrip, Buscopan
  • Engov, Epocler, Neosaldina, Neo Química

Nutritional & Vitamin Supplements: The company also offers supplements under:

  • Tamarine, Biotônico Fontoura, Zero-Cal

Generic Medicines: Hypera supplies affordable generic alternatives, including:

  • Hydroxyzine, Ibuprofen, Losartan Potassium, Omeprazole
  • Paracetamol, Tadalafil, Desogestrel

Company Background

Founded in 1999, Hypera S.A. is headquartered in São Paulo, Brazil, and continues to expand its presence in the pharmaceutical and healthcare industry.

Frequently Asked Questions

  • What is Hypera S.A.'s (BVMF-HYPE3) current market cap?
    As of 07/29/2025, Hypera S.A. (including the parent company, if applicable) has an estimated market capitalization of $2.93 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Hypera S.A. global market capitalization ranking is approximately 4911 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.